MiCAN Technologies

Basic information

Location (HQ)

Kyoto, JP

Other location(s)

Kobe, JP

Spinout from

Independent

Website

CEO

Established in 

Kazuo Miyazaki

2016

Business descriptions

MiCAN is looking for global R&D partners to evaluate our iPS derived dendric myeloid cells in the applications of dengue virus and COVID-19 (SARS-CoV-2) research. Also looking for global supply chain partners (distributors) to handle our ready-to-use kit accessible to the global scientists.

Business field

Independent

Keywords

Human iPSC

Myeloid linage cells

Immature dendritic cells

COVID-19

TRL

7

Key literatures

Company values

Number of filed patents

Not disclosed

Patent IDs

Not disclosed

Total patent value (USD)

No data

Business stage

Spinout / Seed fund stage

Types of requested collaborations

R&D collaboration, international business partners,

Ideal exit model

IPO in other country

Introduction

MiCAN develops iPS-derived myeloid (immature dendritic cells) to be applied for virus research (including dengue and COVID-19) as well as for drug safety applications.

Licensing opportunity

​

Investment opportunity

​